JW Modifier — Drug Discarded / Wasted
Last reviewed: May 2, 2026 by Catherine Rose, CPC · Source: CMS Internet-Only Manual Publication 100-04, Chapter 17, §40
Quick Answer
What is the JW modifier and when does it apply?
JW is a HCPCS Level II modifier that reports a discarded amount of drug from a single-dose container. You bill the administered portion on its own claim line, and the discarded portion on a separate line with the JW modifier appended.
JW is the inverse of JZ. JZ = no waste. JW = waste, on its own line, with the units of waste billed. Never put both modifiers on the same line.
Most common case: weight-based or BSA-based dosing where the calculated dose doesn’t line up with whole vial counts — pediatric oncology, BSA-dosed chemotherapy, weight-based monoclonals where the smallest commercial vial size exceeds the dose. The wasted units are billed on a separate line with JW; the patient is not charged for the wasted portion (it’s reimbursed by Medicare to the practice).
Pay attention. JW reporting accuracy matters financially in two directions. Under-reporting waste (using JZ when JW would apply) leaves Medicare reimbursement on the table for the discarded portion. Over-reporting waste drives up the manufacturer’s reported discarded percentage, which can trigger refund liability under Section 1847A(h) — and is on the OIG’s audit radar. Bill it correctly, document it correctly.
When JW applies vs. when it doesn’t
Apply JW when…
- Drug is from a single-dose container.
- An actual amount of drug was discarded after the patient was dosed (the dose did not consume the full vial).
- The discarded amount can be expressed in billable HCPCS units.
- Discarded amount and administered amount are billed on separate claim lines.
- Patient’s medical record documents the vial size, the dose administered, and the discarded amount.
Do not apply JW when…
- Drug came from a multi-dose vial. Multi-dose vials are exempt from the JZ/JW framework.
- Zero drug was discarded. Use JZ instead.
- You’re combining administered and discarded units on the same claim line. JW must be on a separate line.
- The drug was administered from a shared multi-patient single-dose vial with proper compounding documentation (USP <797> rules apply — some practice patterns may not bill JW). Verify with payer policy.
- The drug is on the Medicare Self-Administered Drug (SAD) exclusion list and was billed under Part D.
Documentation requirements
The patient record must document, at minimum:
- Vial(s) used — size and number of vials drawn into the syringe or IV bag.
- Dose administered — in mg (or appropriate unit) per the order.
- Discarded amount — in mg or in billable units.
- Reason for discarded amount — typically dose-vs-vial mismatch (weight-based, BSA-based, or partial vial drawn for safety / sterility reasons).
- Date and time of administration; signature of the administering professional.
This documentation is what gets pulled in a CMS or payer audit. The standard at audit is whether the record supports the discarded amount on the JW claim line. Reconstruct from the medication administration record (MAR), the infusion-center documentation, and the pharmacy preparation record.
Worked examples (real J-codes from our drug library)
Pediatric Keytruda (BSA-based)
J9271 / pembrolizumab / 1 mg = 1 unit
JW + JZ scenario
- Vial size
- 100 mg / 4 mL single-dose vial
- Dose order
- 2 mg/kg for a 30 kg patient = 60 mg
- Vials drawn
- 1× 100 mg vial
- Administered
- 60 mg (60 units)
- Discarded
- 40 mg (40 units)
Line 1: J9271 × 60 units — (no waste modifier)
Line 2: J9271 × 40 units JW — discarded amount
Two claim lines. Line 1 bills the administered units; line 2 bills the discarded units with JW. The practice receives Medicare reimbursement for the full 100 mg vial, but the discarded portion is reported on its own line. The full Keytruda reference page is at
/drugs/keytruda.
Weight-based monoclonal (Tysabri / natalizumab)
J2323 / natalizumab / 1 mg = 1 unit
JZ (typical)
- Vial size
- 300 mg / 15 mL single-dose vial
- Adult dose
- 300 mg q4wk (flat-dose adult)
- Vials drawn
- 1× 300 mg vial
- Administered
- 300 mg
- Discarded
- 0 mg
JZ on the line, not JW. Adult flat-dose Tysabri uses one whole vial with no waste — the standard JZ scenario. JW would only apply on a hypothetical pediatric or weight-adjusted use that didn’t consume the full vial.
Briumvi loading day 1
J2329 / ublituximab / 1 mg = 1 unit
JZ (typical)
- Vial size
- 150 mg / 6 mL single-dose vial
- Day 1 dose
- 150 mg loading
- Vials drawn
- 1× 150 mg vial
- Administered
- 150 mg
- Discarded
- 0 mg
JZ on the line. Briumvi day-1 and day-15 doses (450 mg) both line up with whole-vial counts — the typical JZ scenario for adult flat-dose drugs. The full Briumvi page is at
/drugs/briumvi.
The manufacturer refund process — Section 1847A(h)
JW reporting feeds the federal manufacturer-refund process under Section 1847A(h) of the Social Security Act. The mechanism:
- Each quarter, CMS computes the percentage of each single-dose-container drug that was billed as discarded (on JW lines) divided by the total amount billed (JW + non-JW).
- If the discarded percentage exceeds the drug’s threshold (generally 10%; some drugs are set at 35%), the manufacturer refunds the excess to Medicare.
- CMS publishes the list of drugs subject to refund and updates it quarterly. The list has grown materially since the program began enforcing in 2023–2024.
This is why JW reporting accuracy matters beyond a single claim. Systematic over-reporting of waste pushes a drug over its threshold and creates manufacturer refund liability that can — in turn — affect the drug’s ASP calculation and downstream pricing.
Threshold details. The default threshold under the rule is 10%. Specific drugs are exempt or have higher thresholds (35%) when the FDA-labeled dose, the vial size, and clinical practice make a higher waste rate operationally unavoidable (typically pediatric-dosed drugs, BSA-dosed oncology, or drugs with very large smallest-vial sizes). Check the current CMS published threshold list before assuming 10%.
Common JW-related denials and how to fix them
| Denial pattern | What it means | Fix |
|---|
| Modifier inconsistent |
JW reported on a multi-dose vial drug or on a Part D claim. |
Verify formulation (single-dose vs. multi-dose) and benefit channel (Part B vs. Part D). Remove JW if the drug is multi-dose or pharmacy-benefit. |
| JW + JZ on same line |
Both modifiers cannot coexist on a single claim line. |
Split into two lines: administered units on one (no waste modifier), discarded units with JW on the other. |
| Units don’t reconcile |
The total units (administered line + JW line) exceed or fall short of a whole-vial multiple by an unexplained amount. |
Recompute: vial size × vials drawn = total units. Total units = administered + discarded. If the math doesn’t check, the documentation needs revisiting. |
| JW on wrong drug |
The drug isn’t on the CMS list eligible for the JW process (rare — usually a multi-dose, oral, or self-admin drug). |
Confirm the drug is from a single-dose container per FDA SPL labeling. |
| NDC missing |
Manufacturer-refund process requires the actual NDC dispensed for the drug. Some payers reject JW lines without the NDC at line level. |
Add the 11-digit NDC to the claim line per payer formatting rules. |
Frequently asked questions
When is the JW modifier required?
Append JW to a separate claim line that reports the discarded portion of a drug from a single-dose container. The administered portion is billed on its own line. JW is required only when there is an actual discarded amount; if zero drug was discarded, use JZ on the line instead.
Can JW and JZ appear on the same claim line?
No. JW and JZ are mutually exclusive on a single claim line. When part of a vial is administered and part is wasted, separate claim lines are required: one line for the administered units (no waste modifier needed on that line) and one line for the discarded units with JW.
What documentation does JW require?
The patient’s medical record must document the vial size used, the amount administered, and the discarded amount. CMS guidance is that JW claims may be subject to medical-record review; documentation that does not support the reported discarded amount may be subject to recoupment. Most practices capture this in the medication administration record (MAR) or the infusion-center documentation system.
How does JW relate to the manufacturer refund process?
Section 1847A(h) of the Social Security Act requires manufacturers of single-dose-container drugs to refund Medicare for discarded amounts that exceed a per-drug threshold (generally 10%, with some drugs at 35%). The discarded amount is computed from JW-modifier claims. Practices that systematically over-report or under-report waste affect the manufacturer’s refund liability and are subject to OIG review.
Does JW apply to multi-dose vials?
No. JW applies only to drugs from single-dose containers (single-dose vials, single-dose syringes, single-dose ampules). Multi-dose vials are exempt because the remaining drug is intended for subsequent doses or patients.
Related references
Sources
- CMS, Internet-Only Manual Publication 100-04 (Medicare Claims Processing Manual), Chapter 17, §40 — Discarded Drugs and Biologicals.
- Section 1847A(h) of the Social Security Act — Manufacturer refund for discarded amounts of single-dose-container drugs.
- CMS, MM12877 / Transmittal 11842 — JZ Modifier Required for No Discarded Amounts of Drugs and Biologicals from Single-Dose Containers or Single-Use Packages.
- CMS, quarterly Section 1847A(h) refund-eligible drug list — published quarterly with each ASP file release.
- HCPCS Level II Long Descriptors, current calendar year — Modifier descriptions JZ and JW.
- OIG Work Plan, current year — Discarded drug billing accuracy review item.
All sources are publicly available federal publications. We do not paywall the underlying citations and we link to them where possible. The methodology by which we resolve source disagreements is described in the Methodology.
Editorial review & sourcing
Reviewed by
Catherine Rose, CPC — Subject Matter Expert, Medical Billing & Coding. Corporate trainer at Elevance Health; expert witness in revenue-cycle and medical-billing matters.
Last reviewed
May 2, 2026
Update triggers
CMS modifier policy change, Section 1847A(h) refund list update, OIG work-plan finding, payer-policy alignment shift, reader-reported correction.
Independence
CareCost Estimate accepts no compensation from drug manufacturers, payers, or PBMs. Full statement on the
Advertising Disclosure.